Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Novo Nordisk (NVO), the company behind popular diabetes and weight loss medications Ozempic and Wegovy, warned that President ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket.

Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

— Days after retaining the Nickles Group, Novo Nordisk also hired Checkmate Government Relations, the new D.C. outpost of a ...

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...